Actively Recruiting
Study Comparing High-Dose Short Radiotherapy to Standard Palliative Radiotherapy for Patients with Localized or Metastatic Renal Cell Carcinoma
Led by Royal Marsden NHS Foundation Trust · Updated on 2025-05-29
24
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new radiotherapy approach for patients with localized or metastatic renal cell carcinoma RCC. This study compares a high-dose short-course radiotherapy schedule to the standard palliative dose radiotherapy in order to understand the feasibility of recruiting patients for these treatments. The trial seeks to enroll at least 24 patients and aims to assess both treatment feasibility and quality of life outcomes. Participants are randomly assigned to one of two treatment groups. The control group receives standard radiotherapy consisting of 30 Gy delivered in 10 fractions over two weeks, while the experimental group receives a higher dose of 30 Gy in 5 fractions on alternate days over two weeks. The study involves pre-treatment planning scans, multiple radiotherapy sessions according to group assignment, and clinic reviews during treatment. Throughout the study, participants undergo quality of life assessments, blood tests, and physical examinations. Follow-up visits occur at 4 weeks post-treatment and then at 3, 6, and 12 months to monitor safety, toxicity, and patient well-being. The primary outcome focuses on feasibility over 24 months, alongside secondary aims to evaluate acute and late toxicity as well as quality of life completion rates. Participants are monitored closely to track these outcomes during the study period.
CONDITIONS
Brief Title
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
Research Team
H
Harshani Green
S
Sijy Pillai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here